Name: Donepezil
Brand: Selleck Chemicals
SKU: S5073
Rating: 5 (4 reviews)

Donepezil (Aricept, Donepezilo) is a piperidine based, potent, specific, non-competitive and reversible inhibitor of acetylcholinesterase (AChE) used for the treatment of mild to moderate dementia of the Alzheimer's type.

Donepezil Chemical Structure

CAS: 120014-06-4

Selleck's Donepezil has been cited by 4 publications

Purity & Quality Control

Batch: S507301 DMSO] 75 mg/mL] false] ] ] false] ] ] false Purity: 99.96%

99.96

Donepezil Related Products

Related Targets	mAChR nAChR AChE	Click to Expand
Related Products	Donepezil HCl PNU-120596 Pilocarpine HCl Pancuronium dibromide Scopolamine (LSM-4015) HBr Benzethonium Chloride CNO (Clozapine N-oxide) Acetylcholine Chloride Amfebutamone (Bupropion) HCl Methscopolamine Arecoline HBr Bethanechol chloride Ipratropium Bromide Otilonium Bromide Choline Chloride Lycorine Darifenacin HBr Rivastigmine Tartrate Acetylcholine iodide Gallamine Triethiodide Hyoscyamine Neostigmine Bromide Atropine Homatropine Methylbromide Succinylcholine Chloride Dihydrate Edrophonium chloride (-)-Huperzine A (HupA) Nitenpyram Cytisine Glycopyrrolate Varenicline Tartrate (CP 526555-18) Trospium chloride Cevimeline HCl hemihydrate Rivastigmine Oxybutynin hydrochloride Chelidonine Galanthamine Atropine sulfate	Click to Expand
Related Compound Libraries	FDA-approved Drug Library Natural Product Library Neuronal Signaling Compound Library CNS-Penetrant Compound Library Anti-alzheimer Disease Compound Library	Click to Expand

Signaling Pathway

AChR Signaling Pathway

Choose Selective AChR Inhibitors

Biological Activity

Description

Donepezil (Aricept, Donepezilo) is a piperidine based, potent, specific, non-competitive and reversible inhibitor of acetylcholinesterase (AChE) used for the treatment of mild to moderate dementia of the Alzheimer's type.

Targets

AChE ^[1]

6.7 nM

In vitro
In vitro	Donepezil has reversible and noncompetitive inhibition effects on AChE. It has 500-1000-fold more selective for AChE over butyrylcholinesterase (BuChE). Short- and long-exposure of SH-SY5Y human neuroblastoma cells to donepezil induces a concentration-dependent inhibition of cell proliferation unrelated to muscarinic or nicotinic receptor blockade or apoptosis. Donepezil reduces the number of cells in the S-G2/M phases of the cell cycle, increases the G0/G1 population, and reduces the expression of two cyclins of the G1/S and G2/M transitions, cyclin E and cyclin B, in parallel with an increase in the expression of the cell cycle inhibitor p21. In addition, donepezil increases action potential-dependent dopamine release and modulates nicotinic receptors of substantia nigra dopaminergic neurons^[1].
Cell Research	Cell lines	retinal ganglion cells (RGCs)
	Concentrations	100 nM-10 μM
	Incubation Time	3 days
	Method	RGC survival after exposure to each reagent (glutamate, donepezil, tacrine, galanthamine, and HA14-1) is measured by calcein-AM staining after 3 days in culture, Briefly, cells are incubated in 1 μM calcein-AM in PBS for 15 minutes at 37℃. After the medium is replaced with fresh PBS, cells are examined under a fluorescence microscope using a fluorescein filter. The total number of surviving RGCs defined as cells with a calcein-AM stained cell body and a process extending at least two cell diameters from the cell body is counted in each well. The number of surviving RGCs without any drug served as a control.

In Vivo
In vivo	Donepezil is slowly absorbed from the gastrointestinal tract and has a terminal elimination half-life of 50-70 hours in young volunteers (>100 hours in elderly subjects). After extensive metabolization in the liver, the parent compound is 93% bound to plasma proteins. Donepezil is metabolized in the liver via the cytochrome P450 system (CYP1A2-, CYP2D6-, CYP3A4-related enzymes). In animals, donepezil is found unchanged in brain, and no metabolites are detected in the nervous tissue. In plasma, urine, and bile, most donepezil metabolites are O-glucuronides. After oral ingestion, peak plasma concentrations are achieved in 3-5 hours and its absortion is not affected by food. Donepezil has linear pharmacokinetics over a dose range of 1-10 mg/day. 96% of circulating donepezil is protein bound^[1].
Animal Research	Animal Models	Age-matched (10-12 weeks old, 21–24 g) male C57BL/6 wild-type and CGRP(−/−) mice
	Dosages	1.5 mg/kg
	Administration	oral

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05345509	Recruiting	Alzheimer Disease	Inventage Lab. Inc.	April 1 2023	Phase 1\|Phase 2
NCT04308304	Completed	Alzheimer''s Disease	Merck Sharp & Dohme LLC	February 16 2021	Phase 1
NCT04617782	Completed	Healthy Subjects	Corium Inc.	December 8 2020	Phase 1
NCT03905096	Completed	Healthy	Boehringer Ingelheim	April 12 2019	Phase 1

References

Chemical Information & Solubility

Molecular Weight	379.49	Formula	C₂₄H₂₉NO₃
CAS No.	120014-06-4	SDF	--
Smiles	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC
Storage (From the date of receipt)	3 years-20°Cpowder	Storage of Stock Solutions Aliquot the stock solutions to avoid repeated freeze-thaw cycles	1 year-80°Cin solvent
Storage (From the date of receipt)	3 years-20°Cpowder		1 month-20°Cin solvent

In vitro
Batch:

DMSO : 75 mg/mL ( (197.63 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.

In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Dilution Calculator Molecular Weight Calculator

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):